Navigation Links
Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d)
Date:5/18/2012

SAN DIEGO, May 18, 2012 /PRNewswire/ -- Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa™ (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world.  Zysa is now ready for clinical use in the EU and countries that recognize the CE Mark. Ocera is in active discussions with potential partners for European sales and marketing.

"IBS-d is a condition affecting millions of people for which no new treatment has been approved in decades," stated Dr. Laurent Fischer, President and CEO of Ocera Therapeutics. "By securing a CE Marking for Zysa, we will, with the right partner, be able to offer a new option for the treatment of this disorder that adversely affects the lives of millions of people."   

Zysa is an oral adsorbent that removes substances that may potentiate gut secretion and contraction, thereby triggering symptoms of IBS. These include abdominal pain, diarrhea and bloating.  Zysa is also marketed as Kremezin™ in Asia to treat chronic kidney disease.

IBS can be extremely debilitating and is associated with economic burden in both direct medical costs and indirect social costs such as absenteeism and lost productivity, along with decreased quality of life.  It represents the most common diagnosis made by gastroenterologists.

In a phase 2 clinical study of patients fulfilling the Rome III criteria for IBS, 26.8% of patients treated with Zysa reported a 50% or more reduction in the number of days with abdominal pain from baseline, compared to only 10.2% of patients treated with placebo (p=0.029) at Week 4. At Week 8, response rates were 32.1 and 25.4% respectively (not statistically significant). Patients trea
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de ... PHIA) anunció hoy su participación en el  Congreso ... sus soluciones cardiológicas más recientes y novedosas, entre ... que conectan a las personas y la tecnología ... ayudar a diagnosticar, guiar los tratamientos y permitir ...
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... Osteotech, Inc. (Nasdaq: OSTE ), a leader in ... announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products ... Society (NASS) 2009 Annual Meeting, taking place November 10th through ... been used in 40 spinal surgeries in the ...
... Inc. (Nasdaq: VVUS ) today announced that Timothy Morris, chief ... Lazard Capital Markets 6th Annual Healthcare Conference. , The VIVUS presentation ... on Wednesday, November 18, 2009 at 1:45 p.m. ET. A ... at http://ir.vivus.com . , About VIVUS ...
Cached Medicine Technology:Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 2Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 3Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 4Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 5VIVUS to Present at Lazard Capital Markets Healthcare Conference 2
(Date:8/31/2015)... ... 2015 , ... healthbeautydistributors.com has been in business since 2005 ... doctor note service to be made available to all patients and family members ... excuse, much less than the average daily pay of workers. , Interested ...
(Date:8/30/2015)... ... August 30, 2015 , ... ProTrailer Party is a new and ... contains 30 styled and detailed presets, allowing FCPX users to immerse the audience ... titles will help film makers save time while adding professional titles to every project. ...
(Date:8/30/2015)... ... August 31, 2015 , ... Negotiating an FDA Import Hold Crisis:, Strategies for ... EDT, http://www.fdanews.com/importholdcrisis , US authorities are holding imports more than ever before, ... , With alerts on an uptick and a new final rule, having a top-notch ...
(Date:8/30/2015)... IL (PRWEB) , ... August 30, 2015 , ... ... is pleased to announce that Partner Daniel M. Kotin was recently elected ... this exclusive organization constitutes the highest degree of peer recognition and outstanding professionalism. ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... the company as the new Global Communications Director for InHealth Media. Mr. ... having spent the last 16 years doing on-air television, producing shows, on air-radio ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer Releases ProTrailer Party for Final Cut Pro X 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 3Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3Health News:InHealth Media Appoints New Global Communications Director 2
... , , LOS ANGELES, Sept. 1 ... Congress, the largest medical tourism congress in the world, announces ... 26-28th 2009 in Los Angeles, California. http://www.medicaltourismcongress.com ... private one-on-one networking sessions will be arranged through special networking ...
... , , , ... the U.S. compression therapy market is necessitating the introduction of ... the concept of evidence-based medicine to educate physicians and encourage ... has spurred the demand for early diagnosis and preventive approaches. ...
... Barcelona, Spain, 1 September: An increasing number of heart ... devices, i.e. cardiac resynchronization therapy (CRT). Recently completed ... provide evidence of a growing number of CRT patients, ... cardiac devices and the simultaneous need for increased efficiency ...
... LOS ANGELES, Sept. 1 FertilityTies, a social network ... well as features that appeal to those struggling with infertility ... FertilityTies is a comprehensive online community affiliated with ... faced with infertility or trying to conceive. www.FertilityTies.com ...
... NATICK, Mass. and BARCELONA, Sept. 1 ... announced long-term data from the Prevention of Sudden Cardiac ... that implantable cardioverter defibrillators (ICDs) were associated with a ... implanted in patients following myocardial infarction (heart attack). ...
... ALISO VIEJO, Calif., Sept. 1 Clarient, Inc. (Nasdaq: ... pathologists, oncologists and the pharmaceutical industry, today announced that it is ... New York City. , , The ... Annual Healthcare Conference at 2:50 pm EDT on Wednesday, September 9. ...
Cached Medicine News:Health News:World's Largest Medical Tourism and Global Healthcare Conference, October 26-28th, Announces Record Attendance, Distinguished Speakers and Sponsors 2Health News:U.S. Compression Therapy Market to Reach $1.16 Billion in 2015, Finds Frost & Sullivan 2Health News:U.S. Compression Therapy Market to Reach $1.16 Billion in 2015, Finds Frost & Sullivan 3Health News:U.S. Compression Therapy Market to Reach $1.16 Billion in 2015, Finds Frost & Sullivan 4Health News:FertilityTies, Social Network for the Fertility-Focused Unveils New Site Design, Unique Features to Help Patients Find Fertility Doctors & More 2Health News:PreSCD II Registry Shows ICDs Lead to 44 Percent Reduction in Mortality for Heart Attack Survivors 2Health News:PreSCD II Registry Shows ICDs Lead to 44 Percent Reduction in Mortality for Heart Attack Survivors 3Health News:Clarient to Present at Upcoming Investment Conferences in New York City 2
... Designed with patient need and ... Orthotic Appliance) family of products effectively ... indications. The Chairback frame attachment provides ... orthosis (LSO) provides superior support for ...
Effectively stabilize and relax your back with the LumboTrain back support....
... to superior immobilization and cervical spine care, one ... already know that the most important function of ... But what you may not know is that ... provides superior immobilization over the leading one-piece rigid ...
Distinct male and female designs for proper anatomical fit. Hip and pelvic components sized independently. Rigid posterior tongue minimizes pelvic rotation. Available in black or white plastic. Aggre...
Medicine Products: